Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Cleary · SciRah

Researcher profile · Semantic Scholar

J. Cleary

Share profile

J. Cleary — researcher profile on SciRah

h-index: 46
Works: 197
Citations: 16K

Most-cited papers

Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial
Y. Janjigian, K. Shitara, M. Moehler, M. Garrido +25 more
2021The Lancet2,244 citations Open access
Semantic Scholar
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
R. Kelly, J. Ajani, J. Kużdżał, T. Zander +23 more
2021New England Journal of Medicine1,420 citations Open access
Semantic Scholar
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
G. Abou-Alfa, T. Macarulla, M. Javle, R. Kelley +22 more
2020The Lancet Oncology857 citations Open access
Semantic Scholar
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Srivatsan Raghavan, Peter S. Winter, Andrew W. Navia, Hannah L. Williams +43 more
2021Cell503 citations Open access
Semantic Scholar
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
A. Zhu, T. Macarulla, M. Javle, R. Kelley +23 more
2021JAMA Oncology460 citations Open access
Semantic Scholar
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
K. Shitara, J. Ajani, M. Moehler, M. Garrido +25 more
2022Nature425 citations Open access
Semantic Scholar
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
T. Bekaii-Saab, F. Ou, D. Ahn, P. Boland +16 more
2019The Lancet Oncology258 citations Open access
Semantic Scholar
Biomarker-Guided Development of DNA Repair Inhibitors
J. Cleary, Andrew J. Aguirre, G. Shapiro, A. D'Andrea
2020Molecules and Cells212 citations Open access
Semantic Scholar
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial
K. Ng, H. Nimeiri, N. McCleary, T. Abrams +24 more
2019Journal of the American Medical Association (JAMA)167 citations Open access
Semantic Scholar
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Razak, J. Cleary, V. Moreno, M. Boyer +17 more
2020Journal for ImmunoTherapy of Cancer115 citations Open access
Semantic Scholar
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
A. Monjazeb, A. Giobbie-Hurder, Ana Lako, Emily M. Thrash +30 more
2021Clinical Cancer Research92 citations Open access
Semantic Scholar
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
J. Harding, S. Piha-Paul, Ronak H. Shah, J. Murphy +24 more
2023Nature Communications84 citations Open access
Semantic Scholar
Spatially-resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intra-tumoral heterogeneity
Hannah L. Williams, Andressa Dias Costa, Jinming Zhang, Srivatsan Raghavan +35 more
2022Cancer Research84 citations Open access
Semantic Scholar
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
G. Shapiro, P. LoRusso, E. Kwak, Susan S. Pandya +14 more
2019Investigational new drugs82 citations
Semantic Scholar
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
J. Cleary, Betty Rouaisnel, A. Daina, Srivatsan Raghavan +8 more
2022npj Precision Oncology80 citations Open access
Semantic Scholar
FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma
J. Cleary, Srivatsan Raghavan, Qi-Biao Wu, Yvonne Y. Li +36 more
2021Cancer Discovery69 citations Open access
Semantic Scholar
Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer
Andressa Dias Costa, Sara A. Väyrynen, A. Chawla, Jinming Zhang +27 more
2022Clinical Cancer Research64 citations Open access
Semantic Scholar
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
A. Mansfield, D. Hong, C. Hann, A. Farago +16 more
2021npj Precision Oncology62 citations Open access
Semantic Scholar
LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
R. Kelly, J. Ajani, J. Kużdżał, T. Zander +16 more
2020Annals of Oncology61 citations Open access
Semantic Scholar
High-throughput dynamic BH3 profiling (HT-DBP) may quickly and accurately predict effective therapies in solid tumors
P. Bhola, E. Ahmed, J. Guerriero, E. Sicinska +15 more
2020Science Signaling52 citations Open access
Semantic Scholar
Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.
A. Zhu, T. Macarulla, M. Javle, R. Kelley +16 more
202147 citations
Semantic Scholar
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.
V. Sridharan, M. Mino-Kenudson, J. Cleary, O. Rahma +17 more
2021Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]41 citations
Semantic Scholar
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
J. Cleary, V. Wang, R. Heist, E. Kopetz +20 more
2021Clinical Cancer Research34 citations Open access
Semantic Scholar
Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Harshabad Singh, R. Keller, Kevin S. Kapner, Julien Dilly +28 more
2023Clinical Cancer Research33 citations Open access
Semantic Scholar
SMARCA4 mutations in carcinomas of the esophagus, esophagogastric junction, and stomach.
Alexander J. Neil, Lei Zhao, Raymond A. Isidro, A. Srivastava +2 more
2023Modern Pathology32 citations Open access
Semantic Scholar
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.
J. Harding, J. Cleary, D. Quinn, I. Braña +16 more
202132 citations
Semantic Scholar
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR
J. Cleary, E. Calvo, V. Moreno, D. Juric +10 more
2020Investigational new drugs30 citations
Semantic Scholar
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Harshabad Singh, Yvonne Y. Li, L. Spurr, A. Shinagare +26 more
2021Clinical Cancer Research29 citations Open access
Semantic Scholar
ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series
M. Ambrosini, M. Del Re, P. Manca, A. Hendifar +17 more
2022JCO Precision Oncology28 citations Open access
Semantic Scholar
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Y. Janjigian, K. Shitara, M. Moehler, M. Garrido +16 more
2023Journal of Clinical Oncology27 citations
Semantic Scholar
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
B. Huffman, Atrayee Basu Mallick, N. Horick, A. Wang-Gillam +13 more
2023JAMA Network Open27 citations Open access
Semantic Scholar
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
L. D. de Klerk, Anuj K. Patel, S. Derks, E. Pectasides +20 more
2021Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan +10 more
2023Nature Communications25 citations Open access
Semantic Scholar
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.
A. Mansfield, D. Hong, C. Hann, A. Farago +16 more
2020Journal of Clinical Oncology25 citations
Semantic Scholar
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
J. Cleary, G. Iyer, D. Oh, I. Mellinghoff +15 more
202025 citations
Semantic Scholar
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
B. Huffman, H. Ellis, A. C. Jordan, William A. Freed-Pastor +8 more
2022Cancers23 citations Open access
Semantic Scholar
FOLFOX Plus Ziv-Aflibercept or Placebo in First-Line Metastatic Esophagogastric Adenocarcinoma: A Double-Blind, Randomized, Multicenter Phase 2 Trial
J. Cleary, N. Horick, N. McCleary, T. Abrams +20 more
2019Cancer23 citations Open access
Semantic Scholar
Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
J. Harding, S. Piha-Paul, Ronak H. Shah, J. Cleary +13 more
2022Journal of Clinical Oncology22 citations
Semantic Scholar
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
V. Cardot-Ruffino, Naima Bollenrucher, L. Delius, S. J. Wang +20 more
2023Journal for ImmunoTherapy of Cancer20 citations Open access
Semantic Scholar
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
R. Kim, A. Leal, A. Parikh, D. Ryan +8 more
2023Cancer Chemotherapy and Pharmacology19 citations Open access
Semantic Scholar
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
R. Corcoran, K. Do, J. Cleary, A. Parikh +15 more
2019Annals of Oncology16 citations Open access
Semantic Scholar
A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
J. Pauff, K. Papadopoulos, F. Janku, A. Turk +16 more
202115 citations
Semantic Scholar
Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
P. Sahgal, B. M. Huffman, D. Patil, W. Chatila +3 more
2021Cancers15 citations Open access
Semantic Scholar
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
R. Kelly, J. Ajani, J. Kużdżał, T. Zander +16 more
202113 citations
Semantic Scholar
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities
N. Perurena, R. Lock, Rachel A Davis, Srivatsan Raghavan +16 more
2023Cell Reports Medicine10 citations Open access
Semantic Scholar
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
M. Mooradian, J. Cleary, A. Giobbie-Hurder, L. Darville +11 more
2023Cancer10 citations Open access
Semantic Scholar
The World Cancer Declaration: time to consolidate wins and work towards 2025.
Sonali E Johnson, Z. Tittenbrun, Y. Romero, J. Torode +10 more
2021The Lancet Oncology10 citations
Semantic Scholar
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
J. Cleary, B. Wolpin, S. Dougan, Srivatsan Raghavan +7 more
2021Clinical Cancer Research9 citations Open access
Semantic Scholar
Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
A. Jatoi, F. Ou, D. Ahn, T. Zemla +16 more
2021The Oncologist9 citations Open access
Semantic Scholar
Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.
A. Monjazeb, A. Giobbie-Hurder, Ana Lako, Anteneh A. Tesfaye +16 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Wolpin×14
Invite
B. Wolpin — researcher profile on SciRah
D. Rubinson×12
Invite
D. Rubinson — researcher profile on SciRah
G. Shapiro×11
Invite
G. Shapiro — researcher profile on SciRah
Andrew J. Aguirre×11
Invite
Andrew J. Aguirre — researcher profile on SciRah

×9

Invite

K. Ng — researcher profile on SciRah

Harshabad Singh×9

Invite

Harshabad Singh — researcher profile on SciRah

Invite

L. Brais — researcher profile on SciRah

Invite

M. Borad — researcher profile on SciRah

Invite

L. Goyal — researcher profile on SciRah

Srivatsan Raghavan×7

Invite

Srivatsan Raghavan — researcher profile on SciRah

Invite

M. Moehler — researcher profile on SciRah

Invite

M. Lei — researcher profile on SciRah